AR024732A1 - Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek. - Google Patents
Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek.Info
- Publication number
- AR024732A1 AR024732A1 ARP000103604A ARP000103604A AR024732A1 AR 024732 A1 AR024732 A1 AR 024732A1 AR P000103604 A ARP000103604 A AR P000103604A AR P000103604 A ARP000103604 A AR P000103604A AR 024732 A1 AR024732 A1 AR 024732A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- pain
- treatment
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
Abstract
Un método para tratar el dolor cronico que comprende administrar a un sujeto que necesita tal tratamiento una composicion que comprende un inhibidor MEK.Un método para tratar el dolor cronico que comprende administrar a un sujeto que necesita tal tratamiento una composicion que comprende un inhibidor MEKseleccionado de un compuesto que se define mediante la formula 1, R1 es hidrogeno, hidroxi, alquilo C1-8, alcoxi C1-8, halo, trifluorometilo, o CN; R2 eshidrogeno; R3, R4 y R5 son independientemente hidrogeno, hidroxi, halo, trifluorometilo, alquilo C1-8, alcoxi C1-8, nitro, CN, o (O o NH)m-(CH2)n-R9, donde R9es hidrogeno, hidroxi, CO2H, o NR10R11; n es 0-4; m es 0-4; R10 y R11 son independientemente hidrogeno o alquilo C1-8, o tomados juntos con el nitrogeno alcual están unidos pueden completar un anillo cíclico de 3 a 10 miembros que opcionalmente contienen uno, dos o tres heteroátomos seleccioandos de O, S, NH oN-C1-8 alquilo; R6 es hidrogeno, alquilo C1-8, alquilo de O=C-C1-8, arilo, aralquilo o cicloalquilo C3-10; R7 es hidrogeno, alquilo C1-8, alquenilo C2-8,alquinilo C2-8, cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9; y donde cualquiera de los grupos alquilo, alquenilo, yalquinilo que anteceden pueden ser no sustituidos o sustituidos por cicloalquilo (o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9), arilo, ariloxi, heteroarilo, o heteroariloxi; o R6 y R7 tomados juntos con el N-O al que están unidos pueden completar un anillo cíclico de 5 a 10miembros, que opcionalmente contienen uno, dos o tres heteroátomos adicionales seleccionado de O, S, o NR10R11. Util en el campo del tratamiento del dolorcronico utilizando inhibidores de MEK. El dolorcronico incluye el dolor neuropático y el dolor por inflamacion cronica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14429299P | 1999-07-16 | 1999-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024732A1 true AR024732A1 (es) | 2002-10-23 |
Family
ID=22507940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103604A AR024732A1 (es) | 1999-07-16 | 2000-07-13 | Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1202726A2 (es) |
| JP (1) | JP2003504400A (es) |
| KR (1) | KR20020012315A (es) |
| CN (1) | CN1373660A (es) |
| AR (1) | AR024732A1 (es) |
| AU (1) | AU5786000A (es) |
| CA (1) | CA2374052A1 (es) |
| CO (1) | CO5300398A1 (es) |
| HU (1) | HUP0202623A3 (es) |
| IL (1) | IL147619A0 (es) |
| NZ (1) | NZ515567A (es) |
| PE (1) | PE20010545A1 (es) |
| PL (1) | PL352684A1 (es) |
| TR (1) | TR200200082T2 (es) |
| WO (1) | WO2001005392A2 (es) |
| ZA (1) | ZA200109907B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU2503A (sh) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CN101486682B (zh) | 2002-03-13 | 2013-08-14 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| DE602004023207D1 (de) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| EP1676837A4 (en) * | 2003-10-08 | 2008-09-10 | Teijin Pharma Ltd | METHOD FOR PRODUCING AN AMINOPYRROLIDINE DERIVATIVE AND AN INTERMEDIATE COMPOUND |
| KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| SI1682138T1 (sl) | 2003-11-19 | 2011-04-29 | Array Biopharma Inc | HETEROCIKLIÄŚNI INHIBITORJI MEK-a |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
| TWI361066B (en) * | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| US8299076B2 (en) | 2005-05-18 | 2012-10-30 | Array Biopharma Inc. | Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide |
| ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2008006032A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
| PL2101759T3 (pl) | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| RU2486181C2 (ru) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ |
| EP2173723B3 (en) | 2007-07-05 | 2014-11-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| WO2009037707A2 (en) | 2007-09-20 | 2009-03-26 | Ramot At Tel Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
| CA2709257C (en) | 2007-12-19 | 2016-12-13 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| ES2422733T3 (es) | 2008-01-09 | 2013-09-13 | Array Biopharma Inc | Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT |
| AU2009204019B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| ES2399384T3 (es) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido fenoxibenzamidas sustituidas |
| WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| EP2491014A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| EP2491016A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| DK2531502T3 (da) | 2010-02-01 | 2014-05-19 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi |
| JP2013542214A (ja) | 2010-10-29 | 2013-11-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換フェノキシピリジン類 |
| JP6147246B2 (ja) | 2011-04-01 | 2017-06-14 | ジェネンテック， インコーポレイテッド | Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法 |
| CN103857395A (zh) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Akt抑制剂化合物和阿比特龙的组合及使用方法 |
| BR112015008113B1 (pt) | 2012-10-12 | 2022-05-24 | Exelixis, Inc. | Novo processo para preparar compostos para uso no tratamento de câncer |
| CA2923835C (en) | 2013-09-11 | 2022-11-29 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| CA3001879A1 (en) | 2015-10-27 | 2017-05-04 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors for the treatment of diabetic peripheral neuropathy |
| CN111479566B (zh) | 2017-10-17 | 2024-05-07 | 归属疗法有限公司 | 用于治疗病毒和细菌感染的新mek抑制剂 |
| JP2022538569A (ja) * | 2019-06-28 | 2022-09-05 | ユニバーシティ オブ コペンハーゲン | 睡眠障害を伴うｃｎｓ障害の治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
| EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| HUP0003731A3 (en) * | 1997-07-01 | 2002-11-28 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| JP2002532415A (ja) * | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
-
2000
- 2000-07-05 HU HU0202623A patent/HUP0202623A3/hu unknown
- 2000-07-05 NZ NZ515567A patent/NZ515567A/xx unknown
- 2000-07-05 KR KR1020027000609A patent/KR20020012315A/ko not_active Application Discontinuation
- 2000-07-05 TR TR2002/00082T patent/TR200200082T2/xx unknown
- 2000-07-05 AU AU57860/00A patent/AU5786000A/en not_active Abandoned
- 2000-07-05 JP JP2001510449A patent/JP2003504400A/ja active Pending
- 2000-07-05 WO PCT/US2000/018347 patent/WO2001005392A2/en not_active Application Discontinuation
- 2000-07-05 CA CA002374052A patent/CA2374052A1/en not_active Abandoned
- 2000-07-05 PL PL00352684A patent/PL352684A1/xx not_active Application Discontinuation
- 2000-07-05 IL IL14761900A patent/IL147619A0/xx unknown
- 2000-07-05 EP EP00943383A patent/EP1202726A2/en not_active Withdrawn
- 2000-07-05 CN CN00809801A patent/CN1373660A/zh active Pending
- 2000-07-13 AR ARP000103604A patent/AR024732A1/es unknown
- 2000-07-14 PE PE2000000705A patent/PE20010545A1/es not_active Application Discontinuation
- 2000-07-14 CO CO00053304A patent/CO5300398A1/es not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109907A patent/ZA200109907B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200200082T2 (tr) | 2002-04-22 |
| WO2001005392A2 (en) | 2001-01-25 |
| PL352684A1 (en) | 2003-09-08 |
| HUP0202623A3 (en) | 2003-03-28 |
| IL147619A0 (en) | 2002-08-14 |
| KR20020012315A (ko) | 2002-02-15 |
| CA2374052A1 (en) | 2001-01-25 |
| ZA200109907B (en) | 2003-02-28 |
| WO2001005392A3 (en) | 2001-07-19 |
| AU5786000A (en) | 2001-02-05 |
| EP1202726A2 (en) | 2002-05-08 |
| PE20010545A1 (es) | 2001-06-04 |
| CN1373660A (zh) | 2002-10-09 |
| JP2003504400A (ja) | 2003-02-04 |
| NZ515567A (en) | 2004-03-26 |
| HUP0202623A2 (hu) | 2002-11-28 |
| CO5300398A1 (es) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024732A1 (es) | Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek. | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| ATE323717T1 (de) | Piperazin-4-phenyl-derivate als inhibitoren der wechselwirkung zwischen mdm2 und mdm2 | |
| DK0880508T3 (da) | Quinazolinderivater som VEGF-inhibitorer | |
| HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
| NO972538L (no) | Nye sulfonamider | |
| TW200510353A (en) | Alpha substituted carboxylic acids as PPAR modulators | |
| DK0589924T3 (da) | Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser | |
| RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
| RU2011108563A (ru) | Способы лечения талассемии | |
| CL2004001167A1 (es) | Compuestos derivados de tiazolidindionas; procedimiento de elaboracion: composicion farmaceutica que los contiene; y su uso en el tratamiento de la diabetes. | |
| PT892793E (pt) | Derivados 2-cianoiminoimidazolo inibidores da pde iv | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| TR199701219T1 (xx) | Benzimidazol bile�ikleri, bu bile�ikleri i�eren ispen�iyar� bile�ikler. | |
| HRP20090264T1 (en) | Phenyl-piperazin methanone derivatives | |
| DE60316672D1 (de) | Polycyclische verbindungen als potenten alpha2-adrenoceptor antagonisten | |
| SE9701304D0 (sv) | Compounds | |
| ES2083972T3 (es) | Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras. | |
| ES2262504T3 (es) | Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4. | |
| DK524283A (da) | Fremgangsmaade til fremstilling af nitrosoureaderivater | |
| FI940568A0 (fi) | Anti-inflammatorisina aineina toimivia oksindoli-1-(N-(alkoksikarbonyyli))karboksamideja ja -1-(N-karboksamido)-karboksamideja | |
| CO5031336A1 (es) | Mezclas fungicidas que contienen carbamatos y un derivado aromatico | |
| ES408605A1 (es) | Procedimiento para preparar oxazoles 2,4,5-trisustituidos. | |
| SE9702534D0 (sv) | Compounds | |
| TW429147B (en) | Pharmaceutical composition for the treatment of CNS disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |